Koch Peter J, Koster Maranke I
Department of Anatomy and Cell Biology, Brody School of Medicine (BSOM) at East Carolina University (ECU), Greenville, NC, United States.
Front Genet. 2021 Aug 6;12:714764. doi: 10.3389/fgene.2021.714764. eCollection 2021.
The last decade has seen a dramatic increase in innovative ideas for the treatment of genetic disorders for which no curative therapies exist. Gene and protein replacement therapies stand out as novel approaches to treat a select group of these diseases, such as certain tissue fragility disorders. Further, the advent of stem cell approaches, such as induced pluripotent stem cells (iPSC) technology, has led to the development of new methods of creating replacement tissues for regenerative medicine. This coincided with the discovery of genome editing techniques, which allow for the correction of disease-causing mutations. The culmination of these discoveries suggests that new and innovative therapies for monogenetic disorders affecting single organs or tissues are on the horizon. Challenges remain, however, especially with diseases that simultaneously affect several tissues and organs during development. Examples of this group of diseases include ectodermal dysplasias, genetic disorders affecting the development of tissues and organs such as the skin, cornea, and epithelial appendages. Gene or protein replacement strategies are unlikely to be successful in addressing the multiorgan phenotype of these diseases. Instead, we believe that a more effective approach will be to focus on correcting phenotypes in the most severely affected tissues. This could include the generation of replacement tissues or the identification of pharmaceutical compounds that correct disease pathways in specific tissues.
在过去十年中,对于尚无治愈疗法的遗传性疾病的创新治疗理念急剧增加。基因和蛋白质替代疗法作为治疗其中某些特定疾病(如某些组织脆性疾病)的新方法脱颖而出。此外,干细胞方法的出现,如诱导多能干细胞(iPSC)技术,已促使再生医学中用于创建替代组织的新方法得以发展。这与基因组编辑技术的发现同时发生,基因组编辑技术能够纠正致病突变。这些发现的 culmination 表明,针对影响单一器官或组织的单基因疾病的新型创新疗法即将出现。然而,挑战依然存在,尤其是对于那些在发育过程中同时影响多个组织和器官的疾病。这类疾病的例子包括外胚层发育异常,即影响皮肤、角膜和上皮附属器等组织和器官发育的遗传性疾病。基因或蛋白质替代策略在解决这些疾病的多器官表型方面不太可能成功。相反,我们认为更有效的方法是专注于纠正受影响最严重组织中的表型。这可能包括生成替代组织或鉴定能够纠正特定组织中疾病途径的药物化合物。